An interventional study of NIV interface with airway washout in Respiratory Insufficiency and Respiratory Failure, sponsored by Fisher and Paykel Healthcare. Not yet recruiting. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Fisher and Paykel Healthcare · Not applicable, Interventional, and Supportive care
Study Overview The goal of this clinical trial is to learn whether an improved non invasive ventilation mask with airway washout can reduce how often people need to breathe and perform as well as standard NIV masks when used with different ventilators, in people receiving NIV therapy for respiratory distress or respiratory insufficiency.
The main question(s) it aims to answer are:
Three iterations of the new mask (vented, non-vented, dual limb) will be compared to standard of care to see if the mask reduces the need to breathe and performs consistently across ventilators compared with usual NIV masks.
________________________________________ What Participants Will Do Participants will wear two different NIV masks, each for one hour, during a single study session lasting approximately 2.5 hours.
Participants will be asked to:
Participants may also choose (optional):
To have three small blood samples taken (These samples are optional, and participants can still take part in the study if they decline them.)
During the study, researchers will collect data from the ventilator, including:
The investigational masks perform as the commercially available comparators delivering the prescibed NIV, with the potential benefit of upper airway and instrumental dead space washout. This should improve RR by approximately 3 BPM. This study is to establish the investigation mask has similar usability as the comparator with improved efficacy, potentially reducing RR. The knowledge gained during this clinical investigation may provide further clinical benefits to patients with respiratory failure.
Non-invasive ventilation (NIV) is a method of delivering respiratory support without using an endotracheal tube. It's a first-line treatment for specific conditions like COPD exacerbations and acute cardiogenic pulmonary edema. NIV aims to improve gas exchange, reduce work of breathing, avoid intubation, and reduce complications.
For patients with COPD exacerbations and acute cardiogenic pulmonary edema NIV is a first line therapy. NIV is also considered for other conditions like acute respiratory failure due to asthma exacerbation and in immunocompromised individuals with acute respiratory insufficiency. Additionally, it can be used in post-operative respiratory failure, for difficult weaning, and to prevent post-extubation failure.
NIV has been shown to result in overall better outcomes than mechanical ventilation with reduced mortality and morbidity, fewer ICU acquired infections improved lung function and shorter ICU stays. The severity of the respiratory insufficiency influences the likelihood of successful NIV. One factor associated with respiratory sufficiency is respiratory dead space. This is the volume in the respiratory apparatus that does not partake in gas exchange and in the ventilated patient includes the volume in the equipment, the conductive airways and pathological respiratory tissue. A high dead-space fraction early in the course of the illness is association with increased risk of death.9 Particularly in patients that have a small tidal volume and high respiratory rate, or patients with an increased physiological dead space due to lung disease, a change in instrumental dead space can have a large impact on alveolar minute ventilation. Improved alveolar ventilation can improve CO2 elimination and help to reduce respiratory acidosis as well as improve oxygen delivery.10, 11 This can consequently reduce the respiratory effort required by the patient. 12 If the physician instead chooses to keep arterial CO2 concentration (PaCO2) constant, a reduction of instrumental dead space will allow a reduction of tidal volume, plateau pressure, driving pressure, or a reduction of the respiratory rate and thus a reduction in work of breathing.
NIV with washout improves ventilation compared to conventional NIV by reducing expired air in each breath. This may result in faster normalization of ventilatory gases and a reduced work of breathing, the patient may improve more rapidly as alveolar ventilation is improved. Or, allow for a reduction in pressure for similar ventilatory benefits, potentially improving NIV tolerance and therapy adherence. In stable COPD patients, NIV with Airway Washout resulted in a significant reduction in minute ventilation compared to conventional NIV. This was approximately 19% lower with OptiNIV compared to conventional NIV.15 In this study minute ventilation will be calculated from the RR and Vt retrieved from the ventilator to asses improvement in ventilation over the study period, this self-control study aims to establish efficacy of airway washout and whether the generation 2 design changes do not impact usability. When airway washout becomes more widely available it may improve NIV therapy efficacy by improving ventilation or reducing the pressure needed for a similar level of ventilatory support.
1,369 studies on the registry are indexed under Respiratory Insufficiency; 264 are open to participants now.
This study's planned enrollment of 60 is close to the median of 60 across 860 interventional studies indexed under Respiratory Insufficiency.
Browse Respiratory Insufficiency studies →Fisher and Paykel Healthcare is the lead sponsor of 86 studies on the registry; 16 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is the arm with the second generation OptiNIV mask with airway washout. this new mask function very much like the commercially available OptiNIV mask but for a wider population as the maximum pressure is 40 not 30 cmH20 and on a wider variety of ventilators now also having a dual limb solution.
Other: NIV interface with airway washout
The standard of care mask the participant is on when they are recruited. this is the comparator.
This is a new design of the OptiNIV mask with airway washout that is commercially available.
respiratory rate
A reduction in respiratory rate of 3 bpm. The RR will be taken off the ventilator as a continuous measure out of the coms protocol we will download. Point measures will also be taken in the event the vent data is corrupted. RR at 10 min intervals will be noted down in the CRF. We expect a normal improvement in ventilation over time but are expecting a steeper improvement in RR in the intervention arm of 3 BPM.
Time frame: 1 hour per arm of continuous ventilator data.
caregiver evaluation
whether the masks usability is similar to a standard of care one. Caregiver that are delegated the task of mask evaluation will complete the CRF on how the mask fits, whether it was easy to provide/initiate therapy and whether they saw a noticeable improvement in the participant. these questionaries are weighted and will qualitatively processed.
Time frame: The CRF will be completed at the end of the intervention period (1 hour) and once the interventional mask is removed if this is at a later timepoint.
vT
comparison of tidal volume
Time frame: 1 hour
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fisher and Paykel Healthcare →